Buy ADB-FUBINACA Powder

Buy ADB-FUBINACA Powder Canada

Buy ADB-FUBINACA Powder Canada , ADB-FUBINACA Powder for sale Manitoba , ADB-FUBINACA Powder vendor New Brunswick , purchase ADB-FUBINACA Powder Ontario

Buy ADB-FUBINACA Powder Buy ADB-Fubinaca Powder is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Agency.

The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

Technical Information Formal Name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide CAS Number: 1445583-51-6 Molecular Formula: C21H23FN4O2 Formula Weight: 382.4 Purity: ?98% Formulation: A neat solid SMILES: O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3 InChi CodeInChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28) InChi Key: ZSSGCSINPVBLQD-UHFFFAOYSA-N DEA Schedule: I Shipping & Storage Information Storage: -20°C Shipping: Room Temperature in continental US; may vary elsewhere Stability: ? 3 years Legality In the United States, ADB-FUBINACA is a Schedule I controlled substance.

Metabolism Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation

Side effects One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.

At least an additional 8 deaths in Hungary in 2015 are linked to the usage of this material, all deaths were youngsters below 21.

WARNING This product is not for human or veterinary use.

Chemical and Structural Characteristics

ADB-FUBINACA is structurally related to indazole-based synthetic cannabinoids. Its molecular design includes functional groups that enhance receptor binding affinity and influence metabolic stability.

Key chemical features include:

• High affinity for cannabinoid receptors (CB1 and CB2)
• Lipophilic structure, allowing it to interact with biological membranes
• Sensitivity to environmental conditions such as heat, light, and oxidation
• Complex metabolic pathways that produce multiple breakdown products